Key result
US primary pulmonary hypertension mortality drops ~44% from 2018 to 2024 despite persistent demographic disparities.
Why the study?
Contemporary national surveillance data focused specifically on deaths coded as primary pulmonary hypertension in the United States beyond 2020 were limited.
Observational (n=1,831)
Yes
Mortality attributed to primary pulmonary hypertension in the US declined substantially between 2018 and 2024, though significant demographic disparities persist.
Answers are grounded in this paper and cite their sources.
Observed decline in I27.0 deaths may reflect care or coding shifts; extends surveillance but leaves causal factors open.
Background/Objectives: Prior U.S. surveillance studies described changes in pulmonary hypertension mortality through 2020, but contemporary national data focused specifically on deaths coded as primary pulmonary hypertension (PPH; ICD-10 I27.0) are limited. We examined temporal, sex, racial, and geographic patterns in I27.0-coded mortality in the United States from 2018 to 2024. Methods: CDC WONDER Underlying Cause of Death data were analyzed. Annual deaths and mortality rates were examined by year, sex, Single Race 6 category, and U.S. Census region. Results: A total of 1831 deaths were coded as I27.0. Annual deaths declined from 344 in 2018 to 199 in 2024, while the exact crude rate declined from 0.105 to 0.059 per 100,000. Women accounted for 69.5% of deaths. Black individuals had a higher age-adjusted mortality rate than White individuals (0.10 vs. 0.06 per 100,000). The South accounted for the largest share of deaths (43.1%), although the West had a marginally higher exact crude rate. Conclusions: Deaths assigned to I27.0 declined substantially during 2018–2024. This trend occurred during a period of major evolution in PAH care, but the ecological design cannot determine whether therapeutic advances caused the decline. Changes in coding, classification, and assignment of underlying cause may also have contributed. Persistent demographic disparities warrant further investigation.
No takes yet. Share an insight, caveat, or question.
Grover et al. (2026) conducted an observational in Primary pulmonary hypertension (n=1,831). Time period (2018-2024) vs. 2018 (baseline) was evaluated on Crude mortality rate per 100,000. Between 2018 and 2024, the US crude mortality rate for primary pulmonary hypertension declined from 0.105 to 0.059 per 100,000, with persistent demographic disparities.
Synapse has enriched 10 related papers. Consider them for comparative context: